

Supplementary material

Wiśniowska-Śmialek S, Rubiś P, Wasilewski G, et al. Differences in early outcomes of left ventricular assist device recipients implanted. Kardiol Pol. 2023.

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1. Clinical, laboratory, echocardiography and hemodynamic characteristics of LVAD recipients at baseline

Parameter	Pre-COVID-19 era (n = 73)	COVID-19 era (n = 31)	P- value
Age [years]	56.1 (10.2)	60.6 (8.5)	0.02
LVAD procedures, n/per year (%)	10–12.2015 — 3 (4.1) 2016 — 15 (20.5) 2017 — 14 (19.2) 2018 — 20 (27.4) 2019 — 21 (28.8)	2020 — 16 (51.6) 2021 — 15 (48.4)	0.77
Type of LVAD, n (%)			
1. HVAD	42 (57.5)	10 (30.4)	0.02
2. HM3	31 (42.5)	21 (69.6)	
Male, n (%)	69 (94.5)	31 (100)	0.1
BMI, kg/m ² , mean (SD)	28.8 (5.0)	27.5 (3.2)	0.35
NYHA, median (IQR)	4 (3.5–4.0)	3.5 (3.0–3.75)	0.006
NYHA, n (%)			
II — 1 (1.4)	II — 1 (1.4)	II — 1 (3.2)	0.02
III — 21 (28.8)	III — 21 (28.8)	III — 20 (64.5)	
IV — 51 (69.8)	IV — 51 (69.8)	IV — 10 (32.3)	
NYHA III–IV, n (%)	72 (98.6)	30 (96.8)	0.83
INTERMACS, mean (SD)	2.96 (0.9)	3.03 (0.6)	0.21
INTERMACS (1–7), n (%)	1 — 6 (8.2) 2 — 11 (15.1) 3 — 37 (50.7) 4 — 19 (26)	1 — 0 2 — 5 (16.1) 3 — 21 (67.7) 4 — 5 (16.2)	0.24
HF etiology, n (%)			
CAD	60 (82.2)	18 (58.1)	0.009
DCM	13 (17.8)	13 (41.9)	
DM type 2, n (%)	33 (45.2)	17 (54.8)	0.37
AF, n (%)	32 (43.8)	20 (64.5)	0.04
COPD, n (%)	5 (6.8)	1 (3.2)	0.48
CKD, n (%)	29 (39.7)	8 (25.8)	0.22
Avarage HR/min, mean (SD)	78.5 (15.9)	76.4 (13.2)	0.68
SVE/24 hour, mean (SD)	570.1 (171.1)	40.1 (125.5)	0.008
VE/24 hour, mean (SD)	3955.2 (489)	1275.6 (196)	0.07

ICD, n (%)	41 (56.2)	14 (43.7)	0.04
CRT-D	8 (10.9)	10 (31.3)	
Non device	24 (32.9)	7 (25.0)	
NT-proBNP, pg/ml, median (IQR)	2587 (673–5867.5)	2258 (839–5235)	0.56
LDL cholesterol, mmol/l, mean (SD)	2.55 (0.86)	2.06 (0.68)	0.02
Creatinine, μ mol/l, median (IQR)	105 (84–124.5)	106 (89–125.0)	0.48
eGFR, ml/min/m ² , median (IQR)	69 (53.0–88.0)	63 (53–83)	0.78
TSH, μ U/ml, median (IQR)	2.35 (1.48–3.46)	2.52 (1.2–3.69)	0.48
Aspat, U/l, median (IQR)	27 (21–35)	25 (22–37)	0.22
Alat, U/l, median (IQR)	24 (17–43)	27 (17–44)	0.36
INR, median (IQR)	1.12 (1.0–1.26)	1.1 (1.03–1.26)	0.77
Hb, g/dl, median (IQR)	12.9 (1.16–1.45)	13.0 (11.5–14.5)	0.94
LVEDd, mm, mean (SD)	72.1 (10.5)	75.8 (9.6)	0.05
EF, %, mean (SD)	15.0 (7.03)	17.8 (11.9)	0.15
TAPSE, mm, mean (SD)	15.8 (4.3)	15.5 (3.8)	0.75
RHC CI, l/min/m ² , mean (SD)	1.8 (0.4)	1.7 (0.3)	0.65
RHC PCWP average, mm Hg mean (SD)	22.04 (9.5)	18.2 (9.7)	0.13
PVR, WU, median (IQR)	3.45 (2–5.4)	3.2 (2.4–5.9)	0.88
PAP average, mm Hg, median (IQR)	34.5 (25–43)	27.3 (17–36)	0.08

Abbreviations: AF, atrial fibrillation; Alat, alanine aminotransferase; Aspat, aminotransferase aspartate; CAD, coronary artery disease; CI, cardiac index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRT-D, cardiac resynchronization therapy with defibrillator; DCM, dilated cardiomyopathy; DM, diabetes mellitus; EF, ejection fraction; Hb, hemoglobin; HF, heart failure; HR, heart rate; ICD, implantable cardioverter-defibrillator; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LVAD, left ventricular assist device; LVEDd, left ventricular end-diastolic diameter; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RHC, right heart catheterization; TAPSE, tricuspid annulus plane systolic excursion; TSH, thyroid stimulating hormone; SVE, supraventricular extrasystole; VE, ventricular extrasystole; WU, Wood unit